PDF(Pubmed)
Abstract：
UNASSIGNED: Shenkang injection (SKI) has been widely used in China for many years for the treatment of kidney disease. The objective of this systematic review was to assess the efficacy of Shenkang injection for the treatment of acute kidney injury (AKI).
UNASSIGNED: A search was conducted across seven databases, encompassing data from the inception of each database through October 8th, 2023. Randomized controlled trials comparing SKI-treated AKI patients with control subjects were extracted. The main outcome measure was serum creatinine (SCr) levels. Secondary outcomes included blood urea nitrogen (BUN), serum cystatin C (CysC), 24-h urine protein (24 h-Upro) levels, APACHE II score and adverse reactions.
UNASSIGNED: This meta-analysis included eleven studies, and the analysis indicated that, compared with the control group, SKI significantly decreased SCr [WMD = -23.31, 95% CI (-28.06, -18.57); p < 0.001]; BUN [WMD = -2.07, 95% CI (-2.56, -1.57); p < 0.001]; CysC [WMD = -0.55, 95% CI (-0.78, -0.32), p < 0.001]; 24-h urine protein [WMD = -0.43, 95% CI (-0.53, -0.34), p < 0.001]; and the APACHE II score [WMD = -3.07, 95% CI (-3.67, -2.48), p < 0.001]. There was no difference in adverse reactions between the SKI group and the control group [RR = 1.32, 95% CI (0.66, 2.63), p = 0.431].
UNASSIGNED: The use of SKI in AKI patients may reduce SCr, BUN, CysC, 24-h Upro levels, and APACHE II scores in AKI patients. The incidence of adverse reactions did not differ from that in the control group. Additional rigorous clinical trials will be necessary in the future to thoroughly evaluate and establish the effectiveness of SKI in the treatment of AKI.
UNASSIGNED: A search was conducted across seven databases, encompassing data from the inception of each database through October 8th, 2023. Randomized controlled trials comparing SKI-treated AKI patients with control subjects were extracted. The main outcome measure was serum creatinine (SCr) levels. Secondary outcomes included blood urea nitrogen (BUN), serum cystatin C (CysC), 24-h urine protein (24 h-Upro) levels, APACHE II score and adverse reactions.
UNASSIGNED: This meta-analysis included eleven studies, and the analysis indicated that, compared with the control group, SKI significantly decreased SCr [WMD = -23.31, 95% CI (-28.06, -18.57); p < 0.001]; BUN [WMD = -2.07, 95% CI (-2.56, -1.57); p < 0.001]; CysC [WMD = -0.55, 95% CI (-0.78, -0.32), p < 0.001]; 24-h urine protein [WMD = -0.43, 95% CI (-0.53, -0.34), p < 0.001]; and the APACHE II score [WMD = -3.07, 95% CI (-3.67, -2.48), p < 0.001]. There was no difference in adverse reactions between the SKI group and the control group [RR = 1.32, 95% CI (0.66, 2.63), p = 0.431].
UNASSIGNED: The use of SKI in AKI patients may reduce SCr, BUN, CysC, 24-h Upro levels, and APACHE II scores in AKI patients. The incidence of adverse reactions did not differ from that in the control group. Additional rigorous clinical trials will be necessary in the future to thoroughly evaluate and establish the effectiveness of SKI in the treatment of AKI.
摘要：
■肾康注射液（SKI）在中国已广泛用于肾脏疾病的治疗多年。本系统评价的目的是评估肾康注射液治疗急性肾损伤（AKI）的疗效。
■在七个数据库中进行了搜索，包含从每个数据库开始到10月8日的数据，2023年。提取比较SKI治疗的AKI患者与对照受试者的随机对照试验。主要结局指标为血清肌酐（SCr）水平。次要结果包括血尿素氮（BUN），血清胱抑素C（CysC），24小时尿蛋白（24h-Upro）水平，APACHEⅡ评分及不良反应。
■这项荟萃分析包括11项研究，分析表明，与对照组相比，SKI显着降低SCr[WMD=-23.31，95％CI（-28.06，-18.57）；p<0.001]；BUN[WMD=-2.07，95％CI（-2.56，-1.57）；p<0.001]；CysC[WMD=-0.55，95％CI（-0.78，-0.32），p<0.001]；24小时尿蛋白[WMD=-0.43，95％CI（-0.53，-0.34），p<0.001]；APACHEII评分[WMD=-3.07，95%CI(-3.67，-2.48)，p<0.001]。SKI组与对照组的不良反应差异无统计学意义[RR=1.32,95%CI(0.66,2.63),p=0.431]。
■在AKI患者中使用SKI可能会降低SCr，BUN,CysC,24小时Upro水平，AKI患者的APACHEII评分。不良反应发生率与对照组无差异。将来还需要进行更严格的临床试验，以彻底评估和确定SKI治疗AKI的有效性。
■在七个数据库中进行了搜索，包含从每个数据库开始到10月8日的数据，2023年。提取比较SKI治疗的AKI患者与对照受试者的随机对照试验。主要结局指标为血清肌酐（SCr）水平。次要结果包括血尿素氮（BUN），血清胱抑素C（CysC），24小时尿蛋白（24h-Upro）水平，APACHEⅡ评分及不良反应。
■这项荟萃分析包括11项研究，分析表明，与对照组相比，SKI显着降低SCr[WMD=-23.31，95％CI（-28.06，-18.57）；p<0.001]；BUN[WMD=-2.07，95％CI（-2.56，-1.57）；p<0.001]；CysC[WMD=-0.55，95％CI（-0.78，-0.32），p<0.001]；24小时尿蛋白[WMD=-0.43，95％CI（-0.53，-0.34），p<0.001]；APACHEII评分[WMD=-3.07，95%CI(-3.67，-2.48)，p<0.001]。SKI组与对照组的不良反应差异无统计学意义[RR=1.32,95%CI(0.66,2.63),p=0.431]。
■在AKI患者中使用SKI可能会降低SCr，BUN,CysC,24小时Upro水平，AKI患者的APACHEII评分。不良反应发生率与对照组无差异。将来还需要进行更严格的临床试验，以彻底评估和确定SKI治疗AKI的有效性。
